Condensed Consolidated Statement of Noncontrolling Interests and Equity - USD ($) $ in Thousands	Total	Noncontrolling Interest - Preferred Operating Partnership	Noncontrolling Interest - Operating Partnership	Noncontrolling Interest - Other	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Balance, beginning of period at Dec. 31, 2018	$ 2,785,422	$ 153,096	$ 218,362	$ 240	$ 1,271	$ 2,640,705	$ 34,650	$ (262,902)
Balance, beginning of period (in shares) at Dec. 31, 2018					127,103,750
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon the exercise of options	1,757				$ 3	1,754
Issuance of common stock upon the exercise of options (in shares)					169,021
Restricted stock grants issued (in shares)					35,022
Restricted stock grants cancelled (in shares)					(1,244)
Compensation expense related to stock-based awards	2,954					2,954
Redemption of Operating Partnership units for stock			(3,310)			3,310
Redemption of Operating Partnership units (in shares)					85,501
Issuance of Preferred D Units in the Operating Partnership in conjunction with acquisitions	23,447	23,447
Net income	102,160	3,164	4,235	(9)				94,770
Other comprehensive loss	(23,993)	(147)	(1,003)				(22,843)
Distributions to Operating Partnership units held by noncontrolling interests	(8,412)	(3,296)	(5,116)
Dividends paid on common stock	(109,523)							(109,523)
Balance, end of period at Mar. 31, 2019	2,773,812	176,264	213,168	231	$ 1,274	2,648,723	11,807	(277,655)
Balance, end of period (in shares) at Mar. 31, 2019					127,392,050
Balance, beginning of period at Dec. 31, 2018	2,785,422	153,096	218,362	240	$ 1,271	2,640,705	34,650	(262,902)
Balance, beginning of period (in shares) at Dec. 31, 2018					127,103,750
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	214,849
Balance, end of period at Jun. 30, 2019	2,828,811	176,108	210,235	259	$ 1,285	2,756,799	(27,476)	(288,399)
Balance, end of period (in shares) at Jun. 30, 2019					128,513,095
Balance, beginning of period at Mar. 31, 2019	2,773,812	176,264	213,168	231	$ 1,274	2,648,723	11,807	(277,655)
Balance, beginning of period (in shares) at Mar. 31, 2019					127,392,050
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon the exercise of options	468				$ 0	468
Issuance of common stock upon the exercise of options (in shares)					17,042
Restricted stock grants issued	2				$ 2
Restricted stock grants issued (in shares)					53,789
Restricted stock grants cancelled (in shares)					(4,786)
Issuance of common stock, net of offering costs (in shares)					930,000
Issuance of common stock, net of offering costs	98,796				$ 9	98,787
Compensation expense related to stock-based awards	3,998					3,998
Redemption of Operating Partnership units for stock			(4,823)			4,823
Redemption of Operating Partnership units (in shares)					125,000
Issuance of Preferred D Units in the Operating Partnership in conjunction with acquisitions	4,575	4,575
Noncontrolling interest in consolidated joint venture	50			50
Conversion of Preferred C Units in the Operating Partnership for Common Operating Partnership Units		(4,374)	4,374
Net income	112,689	3,129	4,754	(22)				104,828
Other comprehensive loss	(41,302)	(254)	(1,765)				(39,283)
Distributions to Operating Partnership units held by noncontrolling interests	(8,705)	(3,232)	(5,473)
Dividends paid on common stock	(115,572)							(115,572)
Balance, end of period at Jun. 30, 2019	2,828,811	176,108	210,235	259	$ 1,285	2,756,799	(27,476)	(288,399)
Balance, end of period (in shares) at Jun. 30, 2019					128,513,095
Balance, beginning of period at Dec. 31, 2019	$ 2,921,694	175,948	205,419	366	$ 1,295	2,868,681	(28,966)	(301,049)
Balance, beginning of period (in shares) at Dec. 31, 2019	129,534,407				129,534,407
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon the exercise of options	$ 944				$ 1	943
Issuance of common stock upon the exercise of options (in shares)					77,400
Issuance of common stock in connection with share based compensation	2,980				$ 1	2,979
Issuance of common stock in connection with share based compensation (in shares)					73,602
Restricted stock grants cancelled	0
Restricted stock grants cancelled (in shares)					(1,767)
Buyback of common stock, net of offering costs	(52,204)				$ (7)			(52,197)
Buyback of common stock, net of offering costs (in shares)					(653,597)
Redemption of Operating Partnership units for stock	0		(330)			330
Redemption of Operating Partnership units (in shares)					8,862
Net income	116,162	3,112	4,877	(6)				108,179
Other comprehensive loss	(89,244)	(563)	(3,807)				(84,874)
Distributions to Operating Partnership units held by noncontrolling interests	(8,505)	(3,178)	(5,327)
Dividends paid on common stock	(117,197)							(117,197)
Balance, end of period at Mar. 31, 2020	2,774,630	175,319	200,832	360	$ 1,290	2,872,933	(113,840)	(362,264)
Balance, end of period (in shares) at Mar. 31, 2020					129,038,907
Balance, beginning of period at Dec. 31, 2019	$ 2,921,694	175,948	205,419	366	$ 1,295	2,868,681	(28,966)	(301,049)
Balance, beginning of period (in shares) at Dec. 31, 2019	129,534,407				129,534,407
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Buyback of common stock, net of offering costs (in shares)	(826,197)
Net income	$ 227,419
Balance, end of period at Jun. 30, 2020	$ 2,745,518	172,542	196,867	419	$ 1,291	2,884,940	(119,256)	(391,285)
Balance, end of period (in shares) at Jun. 30, 2020	129,069,555				129,069,555
Balance, beginning of period at Mar. 31, 2020	$ 2,774,630	175,319	200,832	360	$ 1,290	2,872,933	(113,840)	(362,264)
Balance, beginning of period (in shares) at Mar. 31, 2020					129,038,907
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon the exercise of options	726				$ 0	726
Issuance of common stock upon the exercise of options (in shares)					13,610
Issuance of common stock in connection with share based compensation	4,884				$ 1	4,883
Issuance of common stock in connection with share based compensation (in shares)					60,032
Restricted stock grants cancelled	0
Restricted stock grants cancelled (in shares)					(889)
Buyback of common stock, net of offering costs	(15,615)				$ (1)			(15,614)
Buyback of common stock, net of offering costs (in shares)					(172,600)
Redemption of Operating Partnership units for stock	0		(3,675)		$ 1	3,674
Redemption of Operating Partnership units (in shares)					100,000
Redemption of Preferred D Units in the Operating Partnership for Stock (in shares)					30,495
Noncontrolling interest in consolidated joint venture	68			68
Conversion of Preferred C Units in the Operating Partnership for Common Operating Partnership Units		(2,724)				2,724
Net income	111,257	3,139	5,216	(9)				102,911
Other comprehensive loss	(5,728)	(41)	(271)				(5,416)
Distributions to Operating Partnership units held by noncontrolling interests	(8,386)	(3,151)	(5,235)
Dividends paid on common stock	(116,318)							(116,318)
Balance, end of period at Jun. 30, 2020	$ 2,745,518	$ 172,542	$ 196,867	$ 419	$ 1,291	$ 2,884,940	$ (119,256)	$ (391,285)
Balance, end of period (in shares) at Jun. 30, 2020	129,069,555				129,069,555